Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance
Petar-Bogomil Kanev, Aleksandar Atemin, Stoyno Stoynov, et al.
Seminars in Oncology (2023) Vol. 51, Iss. 1-2, pp. 2-18
Open Access | Times Cited: 22

Showing 22 citing articles:

Drug resistance in ovarian cancer: from mechanism to clinical trial
Ling Wang, Xin Wang, Xueping Zhu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 44
A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells
Petar-Bogomil Kanev, Sylvia Varhoshkova, Irina Georgieva, et al.
Cell Reports (2024) Vol. 43, Iss. 5, pp. 114234-114234
Open Access | Times Cited: 10
Poly-ADP Ribose Polymerase Inhibitors and Combinations in Metastatic Prostate Cancer
Obada Ababneh, Rana R. McKay
Advances in Oncology (2025)
Closed Access
Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition
Naga Shanmugam, Shubham Chatterjee, G. Andrés Cisneros
The Journal of Physical Chemistry B (2025)
Open Access
Predictive Biomarker for SCLC Therapeutics: A Broken Promise or a Complex Disease With Missing Links
Quincy Chu
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 252-255
Closed Access
Acute Impact of Nonoptimal Ambient Temperatures on Plasma Levels of 3000 Proteins in Chinese Adults
Yi Tong Guo, Mohsen Mazidi, Neil Wright, et al.
Environmental Science & Technology (2025)
Open Access
Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine
Cheng Wang, Xiaoran Han, Shaoqiu Kong, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 185, pp. 117955-117955
Closed Access
Bruceine A Inhibits Cell Proliferation by Targeting the USP13/PARP1 Signalling Pathway in Multiple Myeloma
Mengjie Guo, Meng Han, Y. Henry Sun, et al.
Basic & Clinical Pharmacology & Toxicology (2025) Vol. 136, Iss. 5
Open Access
PARP inhibitors in ovarian cancer: mechanisms of resistance and implications to therapy
Sanat Kulkarni, N. Seneviratne, Çağla Tosun, et al.
DNA repair (2025), pp. 103830-103830
Open Access
Effect of defective H2B ubiquitination on the malignancy and repair of DNA double breaks and its significance in lung adenocarcinoma
Zhiyuan An, Ningning Yao, Wenzhong Su, et al.
(2025)
Closed Access
Targeting DNA repair mechanisms: Spirobenzoxazinone and salicylamide derivatives as novel candidates for PARP-1 inhibition in cancer therapy
Abdelrazak M. Kadry, Mai Adel, Samar A. Abubshait, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118173-118173
Closed Access
Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells
Danyang Zhou, Wei Liu, Yanyan Zhang, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 958-958
Open Access
CellTool: An Open-Source Software Combining Bio-Image Analysis and Mathematical Modeling for the Study of DNA Repair Dynamics
Georgi Danovski, Teodora Dyankova-Danovska, Rumen Stamatov, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16784-16784
Open Access | Times Cited: 10
Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors
Lin Zhou, Yicong Wan, Lin Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116733-116733
Open Access | Times Cited: 3
Subcellular NAD+ pools are interconnected and buffered by mitochondrial NAD+
Lena Elise Høyland, Magali R. VanLinden, Marc Niere, et al.
Nature Metabolism (2024) Vol. 6, Iss. 12, pp. 2319-2337
Closed Access | Times Cited: 3
Leveraging PARP-1/2 to Target Distant Metastasis
Mallory I. Frederick, Djihane Abdesselam, Anna Clouvel, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 9032-9032
Open Access | Times Cited: 2
PARP inhibitors in prostate cancer: clinical applications
Hamidreza Saeidi, Mohsen Sarafbidabad
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 2
Mixtures of Three Mortaparibs with Enhanced Anticancer, Anti-Migration, and Antistress Activities: Molecular Characterization in p53-Null Cancer Cells
Renu Wadhwa, Shiming Yang, Hazna Noor Meidinna, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2239-2239
Open Access | Times Cited: 1
The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design
Yinghan Wang, Jingtao Zhang, Xiaochen Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 68, Iss. 1, pp. 18-48
Closed Access | Times Cited: 1
Integrated Computational Pipeline for the Identification of Novel PARP-1 Inhibitors: Hybrid Virtual Screening and Molecular Dynamics Simulations
Guan Wang, Jingjing Guo, Feng Xu, et al.
Research Square (Research Square) (2024)
Open Access
Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge
Chi-Ting Shih, Tzu‐Ting Huang, Jayakumar R. Nair, et al.
Cells (2024) Vol. 13, Iss. 22, pp. 1847-1847
Open Access
Loss of the predicted cell adhesion molecule MPZL3 promotes EMT and chemoresistance in ovarian cancer
Ya-Yun Cheng, Beth L. Worley, Zaineb Javed, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells
Jiuliang Jiang, Pingping Yang, Xinyu Xu, et al.
Anti-Cancer Drugs (2024) Vol. 35, Iss. 9, pp. 789-805
Closed Access
PARP1: Opportunities of Developing New Drugs for an Old Target
Vı́ctor M. Arce, Pablo Iglesias, José A. Costoya
Interdisciplinary cancer research (2024)
Closed Access
Page 1

Scroll to top